Does Lipoxin A4 improve cardiac remodeling and function in mice with diabetes-associated cardiac dysfunction?
Lipoxin A4 mimetics hold potential as a novel strategy to treat cardiac dysfunction in diabetes by improving cardiac remodeling and function independent of glucose control.
BACKGROUND: therapeutic treatment attenuates diabetes-induced cardiac pathology. METHODS: (5 μg/kg, i.p.) or vehicle (0.02% ethanol, i.p.) was administered twice weekly for the final 6 weeks. One week before endpoint, echocardiography was performed within a subset of mice from each group. At the end of the study, mice were euthanized with sodium pentobarbital (100 mg/kg i.p.) and hearts were collected for ex vivo analysis, including histological assessment, gene expression profiling by real-time PCR and protein level measurement by western blot. RESULTS: ameliorated diabetes-induced cardiac inflammation, pro-inflammatory macrophage polarization and cardiac remodeling (especially myocardial fibrosis and cardiomyocytes apoptosis), with ultimate improvement in cardiac function. Of note, this improvement was independent of glucose control. CONCLUSIONS: mimetics holds potential as a novel strategy to treat cardiac dysfunction in diabetes, paving the way for innovative and more effective therapeutic strategies.
Fu et al. (Tue,) studied this question.